What the surveillance found

The first complete winter after the maternal respiratory syncytial virus vaccination programme began has produced a clear and encouraging signal. The UK Health Security Agency reported 63 infants aged under six months admitted with confirmed RSV chest infection to an intensive care unit or high dependency unit during the 2025 to 2026 season. The same 20 NHS trusts had reported 131 such admissions in 2024 to 2025. UKHSA described the difference as a reduction of around 50 per cent. These are serious admissions at the sharpest end of infant respiratory care, so the direction and scale matter to maternity, neonatal and paediatric teams.1, 2

The comparison comes from SARI Watch, England's sentinel system for severe acute respiratory infection. Participating acute trusts submit weekly aggregate numbers of new test confirmed RSV admissions, including the level of care. Sentinel surveillance is designed to detect patterns promptly and consistently rather than count every admission nationally. The use of the same 20 trusts in both seasons strengthens the year to year comparison because a changing group of hospitals could otherwise create an artificial rise or fall. It does not turn the figures into a census of England, and the 68 fewer admissions must not be presented as a national total.1, 2

The broader annual report supports the same direction of travel. Across all ages the 20 sentinel trusts reported 196 RSV admissions to intensive or high dependency care from week 36 of 2025 to week 14 of 2026. Of these, 132 were children under five and 78 were under one. For infants under six months, the report gives 63 cases in 2025 to 2026 and 132 in 2024 to 2025. The news release gives 131 for the earlier season. UKHSA does not explain the one case difference in the published material. Both comparisons amount to a fall of about 52 per cent and support the release's rounded description of about 50 per cent, but the source figures should remain separately attributed rather than silently combined.1, 2

Less severe services also saw a different winter pattern. Emergency department attendances for bronchitis or bronchiolitis among children under one in England totalled 18,137 between weeks 40 and 14. That was lower than 22,585 in 2024 to 2025 and the totals in the two preceding winters. Attendances rose later, peaked from late November into early January, and then declined. These syndromic figures include bronchitis as well as bronchiolitis and are not limited to laboratory confirmed RSV. They therefore provide useful context, not a second measure of vaccine effectiveness.1, 2

Why the result needs a careful reading

The surveillance comparison is observational. It shows that severe infant admissions fell after the programme had time to reach a much larger proportion of pregnancies, but it cannot by itself assign every part of the fall to vaccination. RSV seasons differ in their timing and intensity. Testing practice, healthcare seeking, referral thresholds, neonatal capacity, circulating virus and the characteristics of babies born in each period can also change. UKHSA attributes the improvement strongly to the maternal programme, while the published surveillance design supports an association rather than a randomised estimate of cause.1, 2

The timing makes the vaccine explanation plausible. The maternal programme began in September 2024 in England, Wales and Northern Ireland, and in August 2024 in Scotland. In its first winter, many babies at risk had been born before their mothers could receive the vaccine. By 2025 to 2026, vaccination had been available throughout the pregnancies that produced most of the infant winter cohort. Calling this the first full season describes programme maturity, not a new vaccine or a change in the eligibility week.1, 2

The winter itself was not identical to its predecessor. UKHSA reported that RSV activity began to increase in early November and peaked during December. The annual report also warns that increased testing and case ascertainment may have offset vaccination associated reductions in some surveillance systems. That observation cuts both ways. More testing can reveal cases that would once have gone unrecorded, while a later or milder epidemic can reduce pressure independently of vaccination. A responsible account holds both possibilities alongside the marked fall in severe admissions.1, 2

Small numbers also move more sharply from week to week. The report explicitly cautions that weekly intensive and high dependency admission rates fluctuate because their underlying counts are low. A single season comparison should not be used to promise an individual baby protection from admission, to forecast the next winter, or to claim that intensive care demand has been solved. The strongest conclusion is narrower. Severe RSV admissions among young infants fell substantially in a consistent group of reporting trusts during the first winter in which the maternal programme had operated for a full cycle.1, 2

Uptake shows where protection is still missing

In England, 61.7 per cent of women giving birth between March 2025 and February 2026 had received an RSV vaccine before birth. The figure was 55.6 per cent when measured from the programme's launch to February 2026, reflecting lower coverage during the early months. The latest complete 12 month measure is the more useful description of current reach. Even so, it means a substantial minority of women giving birth did not have a recorded vaccination before delivery. The data do not say why, and it would be wrong to label the whole gap as refusal.1, 3

Missed protection can arise at several points. A woman may not have been offered vaccination, may have received incomplete or conflicting information, may have faced an appointment barrier, or may have chosen not to receive it after discussion. She may have delivered before the planned appointment, moved between services, or been vaccinated without the record reaching the system used for coverage reporting. Teams need to distinguish these routes because a general campaign will not repair a booking failure, a record gap or a service that offers too few practical opportunities.1, 3

Figures from the four nations should not be arranged as a simple league table. The annual report gives 53.7 per cent for pregnant women in Scotland who reached 28 weeks since programme launch and 56.2 per cent for women giving birth in Wales during a stated 12 month period. England's measure uses women giving birth and a different reporting period. Data from Northern Ireland for the 2025 to 2026 season were not available for this part of the report. Different denominators and windows can make unlike systems appear directly comparable when they are not.1, 3

Local maternity services can learn more by separating invitation, offer, acceptance, administration and recording. Coverage should be reviewed alongside gestation at vaccination, place of care, deprivation, ethnicity, language need and transfer between organisations where the data are reliable enough to use safely. The purpose is to locate barriers, not attach blame to communities or individual staff. Small numbers require disclosure control, and any comparison should account for local population and service design before it is turned into a performance judgement.1, 3

The practical task for midwives

The programme is offered throughout the year in every pregnancy from 28 weeks. Maternal vaccination boosts the pregnant woman's antibody response, allowing antibodies to pass through the placenta and help protect the baby after birth. UKHSA advises that vaccination near 28 weeks provides more time for that transfer, while vaccination later in pregnancy can still provide benefit. The offer is therefore not confined to an autumn campaign, even though babies born in late summer and autumn face a higher chance of encountering the winter RSV season early in life.3, 2

For midwives, the first operational requirement is reliable identification. The vaccination discussion and outcome should be visible wherever antenatal care is delivered, including when women move between a community team, hospital clinic and GP practice. A record should distinguish an offer from administration and include the date when a vaccine was given. At later contacts, staff need a simple way to see whether vaccination remains outstanding. That avoids both missed opportunities and repeated conversations that feel like pressure after a woman has made an informed decision.3, 2

The conversation needs to be proportionate and specific. Staff can explain that RSV commonly causes respiratory illness and can lead to bronchiolitis, hospital care and, in a smaller group of young infants, intensive support. They can describe the sentinel finding as encouraging evidence from the first full programme season. They should not imply that vaccination removes all risk, guarantees a particular birth outcome or replaces assessment when a baby becomes unwell. Questions about eligibility, timing, products and clinical circumstances should be answered from current programme guidance rather than memory.3, 2

Access matters as much as wording. An offer that requires another telephone queue, a separate journey or an appointment during working hours may be technically available but practically difficult. Services can examine whether vaccination can be provided during existing antenatal contacts, how women who present after 28 weeks are followed up, and whether information is available in appropriate formats and languages. UKHSA advises women who are past 28 weeks and have not been vaccinated to contact their maternity service or GP practice, so those routes need clear ownership and enough capacity to respond.3, 2

Protection does not remove the need for recognition

A successful vaccination programme changes risk but does not abolish RSV. The annual report still recorded thousands of test confirmed hospital admissions across the participating trusts, and young children remained the largest group among intensive and high dependency cases. Maternity discharge information and health visiting contacts should therefore continue to support parents to recognise breathing difficulty, poor feeding, reduced responsiveness and other signs that require urgent assessment. Vaccination status must never be used to discount symptoms or delay escalation.1, 3

The surveillance data also show why a broad pathway matters. RSV pressure is visible in general practice, emergency departments, paediatric wards and critical care, but each system measures a different part of illness. A fall in one indicator does not ensure the same fall in another age group or care setting. For example, emergency attendances among children aged one to four were slightly higher in 2025 to 2026 than in the previous winter, while the under one total was lower. Nurses should read age, setting and case definition before applying a headline to their service.1, 3

The year round offer is important because RSV has not disappeared outside a neatly defined winter. Seasonal surveillance captures the period of greatest pressure, and UKHSA notes that birth timing changes the likelihood of admission, but there is no risk free month. A woman reaching 28 weeks in spring still needs an offer. A baby born after a late pregnancy vaccination still needs ordinary preventive care and prompt assessment when unwell. The programme is one layer of protection within antenatal, neonatal and community safety rather than a substitute for them.1, 3

Clinical teams also need to preserve trust when discussing uncertainty. It is possible to say that the reduction is substantial, that the programme is the leading explanation offered by UKHSA, and that surveillance cannot prove the cause of every avoided admission. This does not weaken the case for offering vaccination. It tells women what the evidence actually measures. Clear boundaries are particularly important when a striking percentage is repeated in posters, briefings or social media without the sentinel denominator and age group that give it meaning.1, 3

What the next season should establish

A second full season can test whether the fall is sustained. The most useful surveillance will retain stable reporting hospitals while expanding the ability to describe national and regional experience. It should show intensive and high dependency admissions, other hospital admissions and emergency attendances by age with consistent definitions. Publication should continue to explain which trusts reported in each week and how catchment rates were calculated. That transparency makes it possible to separate a real change in severe disease from a change in participation.1, 3, 2

Coverage reporting also needs to become more actionable. National uptake gives direction, but local teams need timely information on missed offers, late vaccination and recording failures. Inequality analysis should be designed with communities and tested for data quality before conclusions are drawn. A low recorded rate may identify poor access, but it can also reflect incomplete transfer between maternity and primary care systems. Measures should support improvement without creating incentives to pressure women or hide uncertainty in the denominator.1, 3, 2

Research and surveillance should examine outcomes over several seasons, account for changes in RSV circulation and testing, and distinguish babies by age and gestation at exposure. Linking vaccination records with outcomes can strengthen estimates, provided the legal basis, information governance and disclosure controls are clear. Evaluation should also look beyond admission counts to practical consequences for families and services, including length and level of care. Those questions require purpose built analysis rather than assumptions based on the headline comparison.1, 3, 2

For now, the message for nursing services is both positive and practical. The first full season brought a large reduction in the most severe recorded outcomes among young infants in sentinel trusts. Coverage remained well short of universal, and the surveillance does not justify a national causal total. Midwives and maternity leaders can act on what is known by making every eligible offer reliable, accessible and accurately recorded, explaining the evidence without promises, and keeping infant recognition and escalation pathways strong.1, 3, 2